Changeflow GovPing Pharma & Drug Safety Halozyme Hypercon Therapeutic Biologics Deliver...
Routine Rule Added Final

Halozyme Hypercon Therapeutic Biologics Delivery Patent US12600763B2

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO granted patent US12600763B2 to Halozyme Hypercon, Inc. covering compositions and methods for delivering therapeutic biologics for disease treatment. The patent comprises 18 claims for particles containing therapeutic biologics suspended in a liquid carrier, with priority to an August 2022 filing date.

What changed

USPTO granted patent US12600763B2 to Halozyme Hypercon, Inc. for compositions and methods of delivering therapeutic biologics for disease treatment. The patent covers particles with therapeutic biologics suspended in liquid carriers and contains 18 claims.

This patent grant gives Halozyme Hypercon exclusive IP rights in the United States, which may affect competitors developing similar therapeutic biologics delivery systems. Manufacturers and pharmaceutical companies should review the claims for potential infringement concerns.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Compositions and methods for the delivery of therapeutic biologics for treatment of disease

Grant US12600763B2 Kind: B2 Apr 14, 2026

Assignee

Halozyme Hypercon, Inc.

Inventors

Paul Brown, Tyler L Carter, Lyndon Fitzgerald Charles, Jr., Chase Spenser Coffman, Daniel Benjamin Dadon, Lisa Liu, Sadiqua Shadbar, Chaitanya Sudrik, Yi Tang, Shankul Vartak

Abstract

The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.

CPC Classifications

A61K 9/14 A61K 9/10 A61K 9/1623 A61K 9/1652 A61K 45/06 A61K 47/14 A61K 38/00 A61K 39/395 C07K 16/00 A61P 35/00

Filing Date

2022-08-08

Application No.

17883427

Claims

18

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600763B2

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting IP licensing Biologics manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!